Jorge Reis-Filho and Caterina Marchiò explain that precision medicine delivery posed a question on how to screen for genetic alterations present in many tumour types but at very low prevalence. They addressed such unmet need in terms of detection of NTRK fusions together with a group of experts on behalf of the ESMO Translational Research and Precision Medicine Working Group.